The news. The narrative. The timeline.
The FDA sent warning letters to 30 telehealth companies over illegal GLP-1 marketing while Novo Nordisk and Hims settled — a regulatory landscape still being written in real time.
Twelve days after a landmark BMJ study, the medical community is reckoning with what the 22% cardiovascular risk figure actually demands of patients and clinicians.
FDA issued warning letters to 30 telehealth companies in February for misleading GLP-1 claims, part of a broader enforcement push on compounded weight-loss drugs.
Chain restaurants from Olive Garden to Cheesecake Factory are redesigning menus around smaller portions and higher protein as GLP-1 users reshape dining habits.
With Easter April 5, U.S. Catholic dioceses report record convert numbers — LA expects 8,598 new members, nearly triple 2023's count.
As GLP-1 adoption scales toward mass market, researchers document downstream effects on body image, dating dynamics, and workplace interactions.
Lancet Global Health modelling links climate-driven heat to mass physical inactivity, projecting 520,000 additional annual deaths and $2.59 billion in lost productivity by 2050.